We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured

Journal Scan / Research · December 07, 2021

Expanding Access to Newer Type 2 Diabetes Medications in Low- and Middle-Income Countries

The Lancet Diabetes & Endocrinology

 

Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Diabetes & Endocrinology
Expanding access to newer medicines for people with type 2 diabetes in low-income and middle-income countries: a cost-effectiveness and price target analysis
Lancet Diabetes Endocrinol 2021 Dec 01;9(12)825-836, Global Health & Population Project on Access to Care for Cardiometabolic Diseases (HPACC)

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading